Kadcyla patent expiry?

When Does the Kadcyla Patent Expiry?

Kadcyla, also known as ado-trastuzumab emtansine, is a targeted therapy medication approved by the US FDA in 2013 for the treatment of HER2-positive breast cancer.

Why Is the Patent for Kadcyla Being Challenged?

Companies are challenging the patent for Kadcyla due to the impending expiry of the patent in 2026. According to DrugPatentWatch.com [1], the Kadcyla patent (US8227381B2) is scheduled to expire on September 16, 2026.

What Does Expiry of the Kadcyla Patent Mean?

The expiry of the Kadcyla patent will allow generic manufacturers to produce and sell a generic version of the medication, potentially increasing access to affordable treatments for patients.

How Will Kadcyla's Expiry Affect Patients With HER2-Positive Breast Cancer?

The expiry of the Kadcyla patent could benefit patients with HER2-positive breast cancer who currently rely on the medication for treatment. With increased competition and generic options available, prices may decrease, making the medication more accessible to those who need it.

Can Biosimilars Enter the Market Before Exclusivity Expiry?

The Biologics Price Competition and Innovation Act (BPCIA) allows for the approval of biosimilars before the expiry of the patent. Biosimilars are generic versions of complex biological products like Kadcyla. If approved, biosimilars can be marketed before the expiry date, further increasing the options for patients and reducing costs.

Sources:

[1] DrugPatentWatch.com - Kadcyla Patent Information www.drugpatentwatch.com

Additional Sources:

* Kadcyla official website - www.kadcyla.com
* FDA approval document - Awaiting access to information